Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5612412 | 0.81 | MAPT (0.51) | SMN1; SMN2KDM4EPOLBAPEX1TDP1 | |
| SCHEMBL31755975 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2KDM4EPOLBAPEX1TDP1 | |
| SCHEMBL2453964 | 0.79 | SMN1; SMN2 (0.66) | SMN1; SMN2KDM4EPOLBAPEX1TDP1 | |
| SCHEMBL13564632 | 0.76 | SMN1; SMN2 (0.61) | SMN1; SMN2KDM4EPOLBAPEX1TDP1 | |
| SCHEMBL6966371 | 0.76 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EPOLBAPEX1TDP1 | |
| SCHEMBL14495384 | 0.76 | KDM4C (0.62) | SMN1; SMN2KDM4EPOLBAPEX1TDP1 | |
| SCHEMBL17787695 | 0.76 | SMN1; SMN2 (0.61) | SMN1; SMN2KDM4EPOLBAPEX1TDP1 | |
| SCHEMBL12770947 | 0.76 | MEN1 (0.65) | SMN1; SMN2KDM4EPOLBAPEX1TDP1 | |
| SCHEMBL11330176 | 0.76 | SMN1; SMN2 (0.61) | SMN1; SMN2KDM4EPOLBAPEX1TDP1 | |
| SCHEMBL31500060 | 0.74 | SMN1; SMN2 (0.69) | SMN1; SMN2KDM4EPOLBAPEX1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364982-A1 | Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof | ONO Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7498323-B2 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICALS CO., LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-7285552-B2 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20070155713-A1 | Nitrogen-containing heterocyclic compounds and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| US-7119091-B2 | Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-10 | — | — | US | disclosed |
| EP-1621540-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | disclosed |
| US-20060019977-A1 | Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1619193-A1 | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-25 | — | — | EP | disclosed |
| EP-1236726-B1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| CN-1533390-A | Pharmaceutical composition comprising triazaspiro [5.5] undecane derivative as active ingredient | СҰҩƷ��ҵ��ʽ���� | 2004-09-29 | — | — | CN | disclosed |
| US-20040106619-A1 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| US-20040097511-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | PANASONIC CORPORATION (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1378509-A1 | DRUGS CONTAINING TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-07 | — | — | EP | disclosed |
| EP-1236726-A1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106619-A1 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | NONO, NAA15, USO1 | SMN1; SMN2 4304/4885KDM4E 348/4885POLB 2192/4885 |
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | CCR1, CCR7, CCR3 | SMN1; SMN2 3376/4885KDM4E 3022/4885POLB 2235/4885 |
| US-20060019977-A1 | Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient | CCR1, ACKR3, CCR10 | SMN1; SMN2 4754/4885KDM4E 3602/4885POLB 2781/4885 |
| US-20040097511-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | CXCR5, CCL11, ACKR3 | SMN1; SMN2 4815/4885KDM4E 2585/4885POLB 2952/4885 |
| US-20070155713-A1 | Nitrogen-containing heterocyclic compounds and use thereof | NNMT, HLA-DRB1, NNT | SMN1; SMN2 1384/4885KDM4E 3967/4885POLB 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.